MedTrace Logo

Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients

NCT00521885 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-10-29

Study results available
· View outcomes & findings →

Summary

A total of 50 patients \>40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled. The patient and study team will be blinded to which drug they are receiving (either Arixtra or Lovenox). Subjects will be examined for any bleeding complications. Subjects will receive drug for a total of 6-14 days while in the hospital. A follow up phone call will be performed by the study team approximately 30 days after discharge from the hospital.

Conditions

  • Venous Thrombosis

Interventions

DRUG

Arixtra (Fondaparinox) 2.5 mg SC Daily

Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm

DRUG

Lovenox 40mg SC Daily

Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm

Sponsors & Collaborators

Principal Investigators

  • Robert Kruklitis, MD · Lehigh Valley Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00521885 on ClinicalTrials.gov